Cost, quality adjusted life-year, and cost effectiveness estimates from different models
| Standard care | Drug therapy | Difference | |
| 5 Year model with no effect on progression | |||
| Relapses | 5.23 | 3.71 | 1.52 |
| Undiscounted costs: | |||
| Relapses | £11000 | £7800 | £3200 |
| IFβ-1b | £0 | £52500 | £52500 |
| Total costs | £11000 | £60300 | £49300 |
| Cost per relapse avoided | £32400 | ||
| Discounted costs: | |||
| Relapse | £10000 | £7100 | £2900 |
| IFβ-1b | £0 | £46600 | £46600 |
| Total cost | £10000 | £53600 | £43600 |
| Cost per relapse avoided | £28700 | ||
| QALY gain: | |||
| Undiscounted | −0.204 | −0.145 | 0.059 |
| Discounted | −0.184 | −0.130 | 0.054 |
| Cost per QALY gained: | |||
| Undiscounted | £831400 | ||
| Costs only discounted | £736200 | ||
| Costs and QALYs discounted | £809900 | ||
| 5 Year model with effect on progression | |||
| Costs | £15200 | £58600 | £43400 |
| QALY gain | 3.08 | 3.21 | 0.13 |
| Cost per QALY gained | £328300 | ||
| 10 Year model with effect on progression: base case | |||
| Costs | £29900 | £104700 | £74800 |
| QALY gain | 5.32 | 5.65 | 0.33 |
| Cost per QALY gained | £228300 | ||
| 10 Year model with effect on progression: best case | |||
| Costs | £29900 | £102200 | £72300 |
| QALY gain | 5.25 | 6.23 | 0.98 |
| Cost per QALY gained | £74500 | ||
| 10 Year model with effect on progression - worst case | |||
| Costs | £29900 | £105400 | £75500 |
| QALY gain | 5.32 | 5.45 | 0.13 |
| Cost per QALY gained | £604600 | ||